Related Experiment Video
Updated: May 1, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
How pharmacokinetic/pharmacodynamic models can inform the development of new HIV medications
Shawn Edgar Miranda1, Saye Khoo1
1Centre for Experimental Therapeutics, University of Liverpool, Liverpool, England, UK.
Abstract:
There remains a need for new HIV medications. This has been challenged by the increasing costs associated with drug discovery and testing. One solution to this issue involves the incorporation of pharmacokinetic/pharmacodynamic (PK/PD) models into the development pipeline. This article provides an overview of how PK/PD models can be used to provide insights to aid this endeavour. This article is part of the Theo Murphy meeting issue 'Evaluating anti-infective drugs'.
Related Concept Videos
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Pharmacodynamic Models: Overview
Pharmacokinetic–Pharmacodynamic Relationship: Model Components
Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model

